Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity.

Yarchoan M, Mohan AA, Dennison L, Vithayathil T, Ruggieri A, Lesinski GB, Armstrong TD, Azad NS, Jaffee EM.

PLoS One. 2019 Oct 31;14(10):e0224600. doi: 10.1371/journal.pone.0224600. eCollection 2019.

2.

Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms.

Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B, Wu C.

Br J Cancer. 2019 Nov;121(10):809-818. doi: 10.1038/s41416-019-0599-y. Epub 2019 Oct 14. Review.

PMID:
31607751
3.

Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression.

Chandrasekaran S, Sasaki M, Scharer CD, Kissick HT, Patterson DG, Magliocca KR, Seykora JT, Sapkota B, Gutman DA, Cooper LA, Lesinski GB, Waller EK, Thomas SN, Kotenko SV, Boss JM, Moreno CS, Swerlick RA, Pollack BP.

Mol Cancer Res. 2019 Dec;17(12):2395-2409. doi: 10.1158/1541-7786.MCR-19-0545. Epub 2019 Sep 23.

PMID:
31548239
4.

Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation.

Deng L, Qian G, Zhang S, Zheng H, Fan S, Lesinski GB, Owonikoko TK, Ramalingam SS, Sun SY.

Oncogene. 2019 Aug;38(35):6270-6282. doi: 10.1038/s41388-019-0877-4. Epub 2019 Jul 17.

PMID:
31316145
5.

Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function.

Mace TA, Ware MB, King SA, Loftus S, Farren MR, McMichael E, Scoville S, Geraghty C, Young G, Carson WE 3rd, Clinton SK, Lesinski GB.

Sci Rep. 2019 Mar 25;9(1):5068. doi: 10.1038/s41598-019-41687-z.

6.

Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer.

Nagaraju GP, Zakka KM, Landry JC, Shaib WL, Lesinski GB, El-Rayes BF.

Int J Cancer. 2019 Sep 15;145(6):1529-1537. doi: 10.1002/ijc.32227. Epub 2019 Mar 19.

PMID:
30801702
7.

Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer.

Ramsey ML, Talbert E, Ahn D, Bekaii-Saab T, Badi N, Bloomston PM, Conwell DL, Cruz-Monserrate Z, Dillhoff M, Farren MR, Hinton A, Krishna SG, Lesinski GB, Mace T, Manilchuk A, Noonan A, Pawlik TM, Rajasekera PV, Schmidt C, Guttridge D, Hart PA.

Pancreatology. 2019 Jan;19(1):80-87. doi: 10.1016/j.pan.2018.11.002. Epub 2018 Nov 10.

PMID:
30497874
8.

Disruption of stromal hedgehog signaling initiates RNF5-mediated proteasomal degradation of PTEN and accelerates pancreatic tumor growth.

Pitarresi JR, Liu X, Avendano A, Thies KA, Sizemore GM, Hammer AM, Hildreth BE 3rd, Wang DJ, Steck SA, Donohue S, Cuitiño MC, Kladney RD, Mace TA, Chang JJ, Ennis CS, Li H, Reeves RH, Blackshaw S, Zhang J, Yu L, Fernandez SA, Frankel WL, Bloomston M, Rosol TJ, Lesinski GB, Konieczny SF, Guttridge DC, Rustgi AK, Leone G, Song JW, Wu J, Ostrowski MC.

Life Sci Alliance. 2018 Oct 26;1(5):e201800190. doi: 10.26508/lsa.201800190. eCollection 2018 Oct.

9.

Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer.

Fisher WE, Cruz-Monserrate Z, McElhany AL, Lesinski GB, Hart PA, Ghosh R, Van Buren G, Fishman DS, Rinaudo JAS, Serrano J, Srivastava S, Mace T, Topazian M, Feng Z, Yadav D, Pandol SJ, Hughes SJ, Liu RY, Lu E, Orr R, Whitcomb DC, Abouhamze AS, Steen H, Sellers ZM, Troendle DM, Uc A, Lowe ME, Conwell DL; Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).

Pancreas. 2018 Nov/Dec;47(10):1213-1221. doi: 10.1097/MPA.0000000000001171.

10.

The Potential of CAR T Cell Therapy in Pancreatic Cancer.

Akce M, Zaidi MY, Waller EK, El-Rayes BF, Lesinski GB.

Front Immunol. 2018 Sep 25;9:2166. doi: 10.3389/fimmu.2018.02166. eCollection 2018. Review.

11.

Interleukin-6/STAT3 Signaling is Prominent and Associated with Reduced Overall Survival in p16 Negative Oropharyngeal Squamous Cell Carcinoma.

Lesinski GB, Nannapaneni S, Griffith CC, Patel M, Chen W, Chen Z, Ahmed R, Wieland A, Shin DM, Chen ZG, Saba NF.

Head Neck Pathol. 2019 Sep;13(3):304-312. doi: 10.1007/s12105-018-0962-y. Epub 2018 Sep 6.

12.

Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients.

Talbert EE, Lewis HL, Farren MR, Ramsey ML, Chakedis JM, Rajasekera P, Haverick E, Sarna A, Bloomston M, Pawlik TM, Zimmers TA, Lesinski GB, Hart PA, Dillhoff ME, Schmidt CR, Guttridge DC.

J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):358-368. doi: 10.1002/jcsm.12251. Epub 2018 Jan 7.

13.

Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.

Kersh AE, Ng S, Chang YM, Sasaki M, Thomas SN, Kissick HT, Lesinski GB, Kudchadkar RR, Waller EK, Pollack BP.

J Clin Pharmacol. 2018 Jan;58(1):7-24. doi: 10.1002/jcph.1028. Epub 2017 Nov 14. Review.

14.

Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells.

Belalcazar A, Shaib WL, Farren MR, Zhang C, Chen Z, Yang L, Lesinski GB, El-Rayes BF, Nagaraju GP.

Cancer. 2017 Dec 15;123(24):4924-4933. doi: 10.1002/cncr.30944. Epub 2017 Aug 25.

15.

Local and Systemic Expression of Immunomodulatory Factors in Chronic Pancreatitis.

Komar HM, Hart PA, Cruz-Monserrate Z, Conwell DL, Lesinski GB.

Pancreas. 2017 Sep;46(8):986-993. doi: 10.1097/MPA.0000000000000896. Review.

16.

Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer.

Nagaraju GP, Wu C, Merchant N, Chen Z, Lesinski GB, El-Rayes BF.

Cancer Lett. 2017 Aug 28;402:110-116. doi: 10.1016/j.canlet.2017.05.021. Epub 2017 Jun 3.

PMID:
28583846
17.

Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo.

Komar HM, Serpa G, Kerscher C, Schwoegl E, Mace TA, Jin M, Yang MC, Chen CS, Bloomston M, Ostrowski MC, Hart PA, Conwell DL, Lesinski GB.

Sci Rep. 2017 May 11;7(1):1787. doi: 10.1038/s41598-017-01973-0.

18.

Mathematical model of chronic pancreatitis.

Hao W, Komar HM, Hart PA, Conwell DL, Lesinski GB, Friedman A.

Proc Natl Acad Sci U S A. 2017 May 9;114(19):5011-5016. doi: 10.1073/pnas.1620264114. Epub 2017 Apr 24.

19.

Laser Capture Microdissection of Pancreatic Acinar Cells to Identify Proteomic Alterations in a Murine Model of Caerulein-Induced Pancreatitis.

Shapiro JP, Komar HM, Hancioglu B, Yu L, Jin M, Ogata Y, Hart PA, Cruz-Monserrate Z, Lesinski GB, Conwell DL.

Clin Transl Gastroenterol. 2017 Apr 13;8(4):e89. doi: 10.1038/ctg.2017.15.

20.

Signaling pathways as therapeutic targets in biliary tract cancer.

Yang J, Farren MR, Ahn D, Bekaii-Saab T, Lesinski GB.

Expert Opin Ther Targets. 2017 May;21(5):485-498. doi: 10.1080/14728222.2017.1306055. Epub 2017 Mar 17. Review.

21.

Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.

Gomez-Chou SB, Swidnicka-Siergiejko AK, Badi N, Chavez-Tomar M, Lesinski GB, Bekaii-Saab T, Farren MR, Mace TA, Schmidt C, Liu Y, Deng D, Hwang RF, Zhou L, Moore T, Chatterjee D, Wang H, Leng X, Arlinghaus RB, Logsdon CD, Cruz-Monserrate Z.

Cancer Res. 2017 May 15;77(10):2647-2660. doi: 10.1158/0008-5472.CAN-16-1986. Epub 2017 Mar 1.

22.

The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.

Farren MR, Hennessey RC, Shakya R, Elnaggar O, Young G, Kendra K, Landesman Y, Elloul S, Crochiere M, Klebanov B, Kashyap T, Burd CE, Lesinski GB.

Mol Cancer Ther. 2017 Mar;16(3):417-427. doi: 10.1158/1535-7163.MCT-16-0498. Epub 2017 Feb 1.

23.

Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.

Talbert EE, Yang J, Mace TA, Farren MR, Farris AB, Young GS, Elnaggar O, Che Z, Timmers CD, Rajasekera P, Maskarinec JM, Bloomston M, Bekaii-Saab T, Guttridge DC, Lesinski GB.

Mol Cancer Ther. 2017 Feb;16(2):344-356. doi: 10.1158/1535-7163.MCT-16-0337. Epub 2016 Nov 3.

24.

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.

Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, Nordquist E, Cruz-Monserrate Z, Yu L, Young G, Zhong X, Zimmers TA, Ostrowski MC, Ludwig T, Bloomston M, Bekaii-Saab T, Lesinski GB.

Gut. 2018 Feb;67(2):320-332. doi: 10.1136/gutjnl-2016-311585. Epub 2016 Oct 21.

25.

A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.

Duggan MC, Jochems C, Donahue RN, Richards J, Karpa V, Foust E, Paul B, Brooks T, Tridandapani S, Olencki T, Pan X, Lesinski GB, Schlom J, Carson Iii WE.

Cancer Immunol Immunother. 2016 Nov;65(11):1353-1364. Epub 2016 Aug 31.

26.

MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches.

Markowitz J, Abrams Z, Jacob NK, Zhang X, Hassani JN, Latchana N, Wei L, Regan KE, Brooks TR, Uppati SR, Levine KM, Bekaii-Saab T, Kendra KL, Lesinski GB, Howard JH, Olencki T, Payne PR, Carson WE 3rd.

Onco Targets Ther. 2016 Sep 29;9:5931-5941. eCollection 2016.

27.

Stromal ETS2 Regulates Chemokine Production and Immune Cell Recruitment during Acinar-to-Ductal Metaplasia.

Pitarresi JR, Liu X, Sharma SM, Cuitiño MC, Kladney RD, Mace TA, Donohue S, Nayak SG, Qu C, Lee J, Woelke SA, Trela S, LaPak K, Yu L, McElroy J, Rosol TJ, Shakya R, Ludwig T, Lesinski GB, Fernandez SA, Konieczny SF, Leone G, Wu J, Ostrowski MC.

Neoplasia. 2016 Sep;18(9):541-52. doi: 10.1016/j.neo.2016.07.006.

28.

Genetic ablation of Smoothened in pancreatic fibroblasts increases acinar-ductal metaplasia.

Liu X, Pitarresi JR, Cuitiño MC, Kladney RD, Woelke SA, Sizemore GM, Nayak SG, Egriboz O, Schweickert PG, Yu L, Trela S, Schilling DJ, Halloran SK, Li M, Dutta S, Fernandez SA, Rosol TJ, Lesinski GB, Shakya R, Ludwig T, Konieczny SF, Leone G, Wu J, Ostrowski MC.

Genes Dev. 2016 Sep 1;30(17):1943-55. doi: 10.1101/gad.283499.116. Epub 2016 Sep 15.

29.

Endoscopic Pancreas Fluid Collection: Methods and Relevance for Clinical Care and Translational Science.

Hart PA, Topazian M, Raimondo M, Cruz-Monserrate Z, Fisher WE, Lesinski GB, Steen H, Conwell DL.

Am J Gastroenterol. 2016 Sep;111(9):1258-66. doi: 10.1038/ajg.2016.297. Epub 2016 Aug 2. Review.

30.

Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.

Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, Bekaii-Saab TS.

Mol Ther. 2016 Jun;24(6):1150-1158. doi: 10.1038/mt.2016.66. Epub 2016 Apr 4.

31.

Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer.

Farren MR, Mace TA, Geyer S, Mikhail S, Wu C, Ciombor K, Tahiri S, Ahn D, Noonan AM, Villalona-Calero M, Bekaii-Saab T, Lesinski GB.

Clin Cancer Res. 2016 May 15;22(10):2565-74. doi: 10.1158/1078-0432.CCR-15-1732. Epub 2015 Dec 30.

32.

Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors.

Ahn DH, Ozer HG, Hancioglu B, Lesinski GB, Timmers C, Bekaii-Saab T.

Oncotarget. 2016 Feb 2;7(5):5306-12. doi: 10.18632/oncotarget.6632.

33.

Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer.

Mace TA, Shakya R, Elnaggar O, Wilson K, Komar HM, Yang J, Pitarresi JR, Young GS, Ostrowski MC, Ludwig T, Bekaii-Saab T, Bloomston M, Lesinski GB.

Oncotarget. 2015 Dec 29;6(42):44509-22. doi: 10.18632/oncotarget.6332.

34.

Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia.

Tseng YC, Kulp SK, Lai IL, Hsu EC, He WA, Frankhouser DE, Yan PS, Mo X, Bloomston M, Lesinski GB, Marcucci G, Guttridge DC, Bekaii-Saab T, Chen CS.

J Natl Cancer Inst. 2015 Oct 12;107(12):djv274. doi: 10.1093/jnci/djv274. Print 2015 Dec.

35.

Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells.

Lesinski GB, Reville PK, Mace TA, Young GS, Ahn-Jarvis J, Thomas-Ahner J, Vodovotz Y, Ameen Z, Grainger E, Riedl K, Schwartz S, Clinton SK.

Cancer Prev Res (Phila). 2015 Nov;8(11):1036-44. doi: 10.1158/1940-6207.CAPR-14-0464. Epub 2015 Aug 14.

36.

Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer.

Ahn-Jarvis JH, Clinton SK, Grainger EM, Riedl KM, Schwartz SJ, Lee ML, Cruz-Cano R, Young GS, Lesinski GB, Vodovotz Y.

Cancer Prev Res (Phila). 2015 Nov;8(11):1045-54. doi: 10.1158/1940-6207.CAPR-14-0465. Epub 2015 Aug 14.

37.

The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.

Martin del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP, Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-Ramirez AC, Markowitz J, Kondadasula SV, Guenterberg KD, McClory S, Karpa VI, Pan X, Olencki TE, Monk JP, Mortazavi A, Tridandapani S, Lesinski GB, Byrd JC, Caligiuri MA, Shah MH, Carson WE 3rd.

J Immunol. 2015 Sep 1;195(5):1995-2005. doi: 10.4049/jimmunol.1400084. Epub 2015 Aug 3.

38.

Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.

Aguilar LK, Shirley LA, Chung VM, Marsh CL, Walker J, Coyle W, Marx H, Bekaii-Saab T, Lesinski GB, Swanson B, Sanchez D, Manzanera AG, Aguilar-Cordova E, Bloomston M.

Cancer Immunol Immunother. 2015 Jun;64(6):727-36. doi: 10.1007/s00262-015-1679-3. Epub 2015 Mar 21.

PMID:
25795132
39.

Intestinal microbial dysbiosis and colonic epithelial cell hyperproliferation by dietary α-mangostin is independent of mouse strain.

Gutierrez-Orozco F, Thomas-Ahner JM, Galley JD, Bailey MT, Clinton SK, Lesinski GB, Failla ML.

Nutrients. 2015 Jan 22;7(2):764-84. doi: 10.3390/nu7020764.

40.

Enhanced bioavailability of lycopene when consumed as cis-isomers from tangerine compared to red tomato juice, a randomized, cross-over clinical trial.

Cooperstone JL, Ralston RA, Riedl KM, Haufe TC, Schweiggert RM, King SA, Timmers CD, Francis DM, Lesinski GB, Clinton SK, Schwartz SJ.

Mol Nutr Food Res. 2015 Apr;59(4):658-69. doi: 10.1002/mnfr.201400658. Epub 2015 Mar 10.

41.

Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease.

Markowitz J, Brooks TR, Duggan MC, Paul BK, Pan X, Wei L, Abrams Z, Luedke E, Lesinski GB, Mundy-Bosse B, Bekaii-Saab T, Carson WE 3rd.

Cancer Immunol Immunother. 2015 Feb;64(2):149-59. doi: 10.1007/s00262-014-1618-8. Epub 2014 Oct 11.

42.

A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.

Sborov DW, Nuovo GJ, Stiff A, Mace T, Lesinski GB, Benson DM Jr, Efebera YA, Rosko AE, Pichiorri F, Grever MR, Hofmeister CC.

Clin Cancer Res. 2014 Dec 1;20(23):5946-55. doi: 10.1158/1078-0432.CCR-14-1404. Epub 2014 Oct 7.

43.

Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.

Yang J, Bill MA, Young GS, La Perle K, Landesman Y, Shacham S, Kauffman M, Senapedis W, Kashyap T, Saint-Martin JR, Kendra K, Lesinski GB.

PLoS One. 2014 Jul 24;9(7):e102983. doi: 10.1371/journal.pone.0102983. eCollection 2014.

44.

Bioactive compounds or metabolites from black raspberries modulate T lymphocyte proliferation, myeloid cell differentiation and Jak/STAT signaling.

Mace TA, King SA, Ameen Z, Elnaggar O, Young G, Riedl KM, Schwartz SJ, Clinton SK, Knobloch TJ, Weghorst CM, Lesinski GB.

Cancer Immunol Immunother. 2014 Sep;63(9):889-900. doi: 10.1007/s00262-014-1564-5. Epub 2014 Jun 4.

45.

Dietary α-mangostin, a xanthone from mangosteen fruit, exacerbates experimental colitis and promotes dysbiosis in mice.

Gutierrez-Orozco F, Thomas-Ahner JM, Berman-Booty LD, Galley JD, Chitchumroonchokchai C, Mace T, Suksamrarn S, Bailey MT, Clinton SK, Lesinski GB, Failla ML.

Mol Nutr Food Res. 2014 Jun;58(6):1226-38. doi: 10.1002/mnfr.201300771. Epub 2014 Feb 17.

46.

A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.

Monk P, Lam E, Mortazavi A, Kendra K, Lesinski GB, Mace TA, Geyer S, Carson WE 3rd, Tahiri S, Bhinder A, Clinton SK, Olencki T.

J Immunother. 2014 Apr;37(3):180-6. doi: 10.1097/CJI.0000000000000023.

47.

A mathematical model for pancreatic cancer growth and treatments.

Louzoun Y, Xue C, Lesinski GB, Friedman A.

J Theor Biol. 2014 Jun 21;351:74-82. doi: 10.1016/j.jtbi.2014.02.028. Epub 2014 Mar 1.

48.

A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.

Markowitz J, Luedke EA, Grignol VP, Hade EM, Paul BK, Mundy-Bosse BL, Brooks TR, Dao TV, Kondalasula SV, Lesinski GB, Olencki T, Kendra KL, Carson WE 3rd.

J Immunother. 2014 Jan;37(1):55-62. doi: 10.1097/CJI.0000000000000009.

49.

PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.).

Nicholas C, Yang J, Peters SB, Bill MA, Baiocchi RA, Yan F, Sïf S, Tae S, Gaudio E, Wu X, Grever MR, Young GS, Lesinski GB.

PLoS One. 2013 Sep 30;8(9):e74710. doi: 10.1371/journal.pone.0074710. eCollection 2013.

50.

Pancreatic cancer-associated stellate cells: A viable target for reducing immunosuppression in the tumor microenvironment.

Mace TA, Bloomston M, Lesinski GB.

Oncoimmunology. 2013 Jul 1;2(7):e24891. Epub 2013 May 7.

Supplemental Content

Loading ...
Support Center